Immunai and Boehringer partner to identify T-cell targets
Immunai and Boehringer Ingelheim have entered a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases. The…
26 Jun 2026
Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval
Earlier this year, Ionis’ CEO Brett Monia said that Tryngolza (olezarsen) would become the company’s first fully owned blockbuster drug, with that forecast having just become more likely following a…
26 Jun 2026
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Absci Corporation has secured $100m in an underwritten offering while reporting positive first-in-human (FIH) data for its lead candidate ABS-201, leaving the biopharma company poised to push the drug’s clinical…
26 Jun 2026
Ionis grants Recordati rights to zilganersen for Alexander disease
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US. Ionis…
26 Jun 2026
BIO 2026: Former FDA staff question agency’s “radical transparency” approach
The US Food and Drug Administration (FDA)’s “radical transparency” approach may have provided a more direct method, but it has also meant lax standards around information disclosed in policy announcements,…
25 Jun 2026
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
Merck KGaA has agreed to acquire life sciences company Bio-Techne Corporation for $11.3bn, representing one of the largest financial outlays by a drugmaker so far this year. As per the…
25 Jun 2026
MSD’s Keytruda-Padcev combo secures EC approval for MIBC
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC). The authorisation applies to…